目的：分析疏肝调脾通腑汤联合靶向治疗及化疗对肝郁脾虚型晚期结直肠癌患者免疫功能、疲乏水平及生存质量的影响。方法：选取2021年2月至2024年8月我院肿瘤科收治的肝郁脾虚型晚期结直肠癌患者90例，按随机数字表法分为对照组（n=45）和试验组（n=45）。对照组给予贝伐珠单抗联合化疗或者呋喹替尼联合化疗治疗，试验组在对照组治疗基础上给予疏肝调脾通腑汤治疗，两组均治疗3个月。比较治疗后两组患者的临床疗效、中医证候疗效、免疫功能、疲乏水平及生存质量，并记录不良反应发生情况。结果：治疗后，试验组患者疾病客观缓解率（40.00%）与对照组（31.11%）比较，差异无统计学意义（P>0.05）；试验组患者中医证候疗效（93.33%）高于对照组（75.56%）（P<0.05）。治疗后，试验组患者外周血CD3⁺、CD4⁺以及CD4⁺/CD8⁺水平较治疗前上升，且均高于对照组（P<0.05）；两组患者Piper疲乏修订量表（PFS-R）躯体感觉疲乏、行为疲乏、情感疲乏、认知情绪疲乏各维度得分和PFS-R总分较治疗前均下降，且试验组PFS-R各维度得分和PFS-R总分均低于对照组（P<0.05）。治疗后，两组患者结直肠癌生活质量专用量表（QLQ-CR38）功能领域得分较治疗均前上升，且试验组高于对照组（P<0.05）；两组患者QLQ-CR38症状领域得分较治疗前均下降（P<0.05），且试验组低于对照组（P<0.05）。治疗期间，试验组不良反应发生率为57.78%（26/45），低于对照组的77.78%（35/45）（P<0.05）。结论：对于肝郁脾虚型晚期结直肠癌患者，疏肝调脾通腑汤有助于提升患者的中医证候疗效，改善患者免疫功能，降低疲乏水平，继而改善其生存质量。

Objective： To analyze the influence of Shugan Tiaopi Tongfu decoction combined with targeted therapy and chemotherapy on immune function， fatigue level and quality of life in patients with liver stagnation and spleen deficiency type of advanced colorectal cancer.Methods： 90 patients with advanced colorectal cancer of liver stagnation and spleen deficiency type in department of oncology of our hospital were selected from February 2021 to August 2024， and were divided into the control group （n=45） and the experimental group （n=45） according to the random number table method. The control group was given bevacizumab combined with chemotherapy or fruquintinib combined with chemotherapy， while the experimental group was given Shugan Tiaopi Tongfu decoction on the basis of the treatment of control group， and both groups were treated for 3 months. The clinical efficacy， TCM syndrome efficacy， immune function， fatigue level and quality of life of the patients were compared between the two groups after the treatment， and the occurrence of adverse reactions was recorded.Results： After treatment， there was no statistical difference in the disease objective response rate between the experimental group （40.00%） and the control group （31.11%） （P>0.05）. After treatment， the TCM syndrome efficacy in the experimental group （93.33%） was higher than that in the control group （75.56%） （P<0.05）. The levels of peripheral blood CD3⁺， CD4⁺ and CD4⁺/CD8⁺ of patients in the experimental group after treatment rose compared with those before treatment， and were higher than those in the control group （P<0.05）. After treatment， the scores of dimensions of somatosensory fatigue， behavioral fatigue， emotional fatigue and cognitive emotional fatigue and total score of Piper Fatigue Scale-Revised （PFS-R） of patients in the two groups declined compared with those before treatment， and the above scores in the experimental group were lower than those in the control group （P<0.05）. After treatment， the score of functional area of Quality of Life Questionnaire-Colorectal Cancer （QLQ-CR38） of patients in the two groups increased， and the score was higher in experimental group （P<0.05）， and the score of QLQ-CR38 symptom area in both groups reduced compared to before treatment （P<0.05）， and the score of patients in the experimental group was lower than that in the control group （P<0.05）. During treatment， the incidence of adverse reactions in the experimental group was 57.78% （26/45）， which was lower than 77.78% （35/45） in the control group （P<0.05）.Conclusion： For patients with advanced colorectal cancer of liver stagnation and spleen deficiency type， Shugan Tiaopi Tongfu decoction is helpful to enhance the TCM syndrome efficacy， improve the immune function， reduce the fatigue level， and then improve the quality of life.